Dani

Denmark on Friday reduced its annual growth outlook to 1.4% with 3%, to a large extent from the weak expectations for the pharmaceutical giant Novo nordisk.

In recent years, Denmark has recorded a strong annual growth, and its economy increased by 3.7%last year, to a large extent enhanced by pharmaceutical exports.

The Danish Pharmaceutical Giant Novo Nordisk makes drugs weighing Azempsic and Wegovy blockbuster.

The Ministry of Economy noted that US exports declined significantly in early 2025 after a huge thorns at the end of 2024, due to both the increase in the inventory and the increase in the weight loss drugs that saw that Novo was losing the market share.

Genetic medicines also squeeze sales opportunities in the US, the report said.

The European Pharmaceutical Sector was deployed this year The threat of high tariffs on the USAlthough now certainty has been secured EU.

The Denmark Ministry said the US tariffs also weighed its growth forecast.

“Growth in the first quarter of 2025 was also weak than previously expected. Along with the US tariff increased and down, adjusted expectations for the pharmaceutical industry, this has led to a significant adjustment of GDP growth in 2025,” the statement said, Google Translate said.

However, the ministry emphasized that, despite the smaller growth outlook, its economy remains strong in general, and high employment and inflation are supposed to be below 2% on the annual basis.

Meanwhile, it revised the growth forecast by 2026 above, up to 2.1% of 1.4%, on expectations for higher private and public consumption.

This news story and will soon be updated.